Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders

J Med Chem. 2010 Mar 25;53(6):2345-53. doi: 10.1021/jm9012906.
No abstract available

MeSH terms

  • Arthritis, Rheumatoid / drug therapy*
  • Arthritis, Rheumatoid / enzymology
  • Chronic Disease
  • Clinical Trials, Phase II as Topic
  • Crystallography, X-Ray
  • Enzyme Inhibitors / chemistry*
  • Enzyme Inhibitors / metabolism
  • Enzyme Inhibitors / therapeutic use*
  • Humans
  • Indoles / chemistry
  • Indoles / metabolism
  • Indoles / therapeutic use
  • Inflammatory Bowel Diseases / drug therapy*
  • Inflammatory Bowel Diseases / enzymology
  • Models, Molecular
  • Molecular Structure
  • Phenylurea Compounds / chemistry
  • Phenylurea Compounds / metabolism
  • Phenylurea Compounds / therapeutic use
  • Protein Binding
  • Psoriasis / drug therapy
  • Psoriasis / enzymology
  • Pyridones / chemistry
  • Pyridones / therapeutic use
  • Pyrimidines / chemistry
  • Pyrimidines / therapeutic use
  • Treatment Outcome
  • p38 Mitogen-Activated Protein Kinases / antagonists & inhibitors*
  • p38 Mitogen-Activated Protein Kinases / metabolism

Substances

  • Enzyme Inhibitors
  • Indoles
  • Phenylurea Compounds
  • Pyridones
  • Pyrimidines
  • SCIO-469
  • VX 702
  • pamapimod
  • p38 Mitogen-Activated Protein Kinases